During the 15th Annual Healthcare Industry Leadership Virtual Conference, A&M experts discussed how COVID-19 has propelled the biotech and pharmaceutical industry – vaccine production, research and innovation and opportunities for investment – tenfold in just a few short months.
In this session, the panelists also discussed:
- Near- and long-term industry outlook
- Expanded patient access for clinical trials
- Developing regulatory challenges
- Emerging players and platforms
- Expanding role for telehealth
Panel Moderator:
Dr. Keith Ghezzi, Managing Director, A&M Healthcare Industry Group
Speakers:
Jacques Mulder, former Managing Director, A&M Healthcare Industry Group
Peter Urbanowicz, Managing Director and Co-Head of A&M's Healthcare Industry Group
Watch the other panel sessions here:
Healthcare Systems in the COVID-19 Era
Diversity & Inclusion in Healthcare Organizations
Contract Research Organisations M&A Market
March 28, 2025
Rising cost pressures, stricter regulatory demands and advancements in emerging therapeutics are intensifying competition within the industry. These dynamics are fuelling the demand for greater efficiency in development lifecycles, creating significant opportunities for outsourced providers like Contract Research Organisations (CROs).
Healthcare Workforce Predictions for 2025
March 19, 2025
The healthcare landscape in 2025 is marked by a complex interplay of financial pressures, persistent workforce shortages, and rapid technological advancements. While healthcare providers have stabilized post-pandemic, they face shrinking revenues coupled with escalating workforce expense, which now comprise a significant portion of total expenses.
Mass General Brigham is Redefining ROI Through the Lens of its Mission to Improve Human Health
March 18, 2025
How do you fundamentally redefine “ROI”? Niyum Gandhi, CFO of Mass General Brigham, the largest employer in New England and the largest medical research organization in the world, shares about his Moonshot to do just that.
The Clock is Ticking: Why Health Plans Must Act Now to Maximize Star Ratings Before the 2026 HEI Update
March 12, 2025
The October 2026 Star Ratings release presents both an opportunity and a challenge for health plans as they navigate uncertain Health Equity Index (HEI) changes. With evolving CMS equity-focused metrics, shifting data collection requirements, and potential weighting adjustments, health plans must take immediate action to optimize their Star Ratings before potential regulatory shifts in 2027.
